Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 583 publications

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.

Journal: Investigational new drugs
Published: August 11, 2025

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Journal: Biochemical pharmacology
Published: July 14, 2025

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.

Journal: EJNMMI radiopharmacy and chemistry
Published: July 03, 2025

Talazoparib for prostate cancer and breast cancer.

Talazoparib for prostate cancer and breast cancer.

Journal: Australian prescriber
Published: June 26, 2025

The emerging role of PARP inhibitors in prostate cancer: A narrative review.

The emerging role of PARP inhibitors in prostate cancer: A narrative review.

Journal: Cancer treatment reviews
Published: June 16, 2025

Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma.

Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma.

Journal: Clinical & experimental metastasis
Published: June 05, 2025

Corrigendum to "Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux" [Biochem. Pharmacol. 199 (2022) 115024].

Corrigendum to "Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux" [Biochem. Pharmacol. 199 (2022) 115024].

Journal: Biochemical pharmacology
Published: June 01, 2025

Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma.

Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma.

Journal: Frontiers in immunology
Published: May 20, 2025

Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa.

Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa.

Journal: Discover oncology
Published: May 09, 2025

Toxicities of PARP inhibitors in genitourinary cancers.

Toxicities of PARP inhibitors in genitourinary cancers.

Journal: Current opinion in urology
Published: May 08, 2025

Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy.

Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy.

Journal: Pathology, research and practice
Published: May 05, 2025

Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis.

Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis.

Journal: International journal of medical sciences
Published: May 05, 2025
Showing 1-12 of 583

Last Updated: 10/31/2025